Meeting ID: 981 2806 6231 Passcode: 848194 One tap mobile +16468769923,,98128066231# US (New York) +16465189805,,98128066231# US (New York)
Dial by your location +1 646 876 9923 US (New York) +1 646 518 9805 US (New York) Meeting ID: 981 2806 6231 Find your local number: https://meetmsk.zoom.us/u/acLK4eNRzf
Day 1 Course Schedule - March 20, 2023
*Course times (Eastern Standard Time)
Time (EST)
Topic:
Presenter(s):
11:00-11:30am
Intro
Jedd, Maggie, Ushma, Ruth
11:30-12:30pm
Tumor vaccines/viruses
Dr. Dmitriy Zamarin
12:30-1:10pm
Agonist Antibodies
Dr. Neil Segal
1:10-1:20pm
10 min break
BREAK
1:20-2:20pm
Mentorship lunch & learn
Dr. Ruth Gotian
2:20-3:15pm
Mentorship Session 1: Building your research team (mentoring students & post-docs, finding and working with internal and external collaborators) (Small Groups)
Dr. Kathy Panageas Dr. Marcel van den Brink Dr. Chris Klebanoff
3:15-3:25pm
10 min break
BREAK
3:25-4:25pm
Microbiome/tumors
Dr. Gretchen Diehl
4:25-5:00pm
Bone Marrow Transplantation (the first immunotherapy)
Dr. Marcel van den Brink
March 2023- Immuno-Oncology for the Translational Researcher Short Course (ITRSC)
About this course
The Memorial Sloan Kettering Cancer Center (MSKCC) Immuno-oncology for the Translational Researcher Short Course (ITRSC) is a cancer education and research experience that will enable eligible junior NCI-funded faculty to learn about tumor immunology, current immunotherapy-based clinical practice and cutting-edge translational research under the mentorship of expert MSKCC faculty. Program participants will attend an intensive 3-day virtual course, led by those centrally involved in basic and clinical immuno-oncology research. ITRSC participants will also have an opportunity to seek additional mentorship and guidance from world experts on immuno-oncology.
The objective of the ITRSC is to engage participants in an in-depth and participatory educational experience covering the topics relevant to clinical immunotherapy research and practice today: checkpoint blockade, novel immunomodulatory antibodies, cellular therapy, immune-monitoring, clinical trial design and development and points of integration with traditional cancer therapy.